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Abstract 
Review on t(8;9)(q24;p13) /MYC, with data on 
clinics, and the genes implicated. 
Clinics and pathology 
Disease 
B-cell acute lymphoblastic leukemia (ALL) and 
non-Hodgkin lymphoma (NHL) 
Phenotype/cell stem origin 
There were 5 cases of ALL (L3-ALLs and CD10+ 
ALLs in 2 cases each), 11 cases of diffuse large B-
cell lymphoma (DLBCL), 7 cases of unclassifiable 
B-cell lymphoma, one case of follicular lymphoma, 
and one case of diffuse mixed small and large cell 
lymphoma (Levine et al., 1989; Nacheva et al., 
1993; Dunphy et al., 2003; D'Achille et al., 2006; 
Bertrand et al., 2007; Le Gouill et al., 2007; 
Christie et al., 2008; Johnson et al., 2009; 
Subramaniyam et al., 2011). 
Epidemiology 
Twenty five cases are available.  
There were 12 male and 13 female patients, median 
age was 63 years (range 42-90 years).  
In a review of NHLs with a t(14;18)(q32;q21), the 
incidence of MYC translocations was 5%, and the 
incidence of t(8;9)(q24;p13) was 1% (Johansson et 
al., 1995). 
Prognosis 
Median survival was 4 months (see figure). 
However, patients with an ALL died at 1, 1, 1.5, 
and 1.5 months.  
Median survival of patients with NHL was 6 
months, and 3 out of 19 NHL patients were still 
alive 5 years after diagnosis (16%). 
Cytogenetics 
Cytogenetics morphological 
A t(14;18)(q32;q21) was present in 24 of 25 cases, 
including 5 of the 5 cases of ALL, a complex 
karyotype was found in 24 of 25 cases.  
Trisomy 7 and 12 were found in seven cases each, 
trisomy 11 and 21, and del(6q) in four cases each, 
trisomy 20 in three cases, trisomy 8, 13, and 18, 
t(1;22)(q21;q11), del(3p), and del(3q) in two cases 
each. 
Genes involved and 
proteins 
Breakpoints occurred close to MYC on 
chromosome 8 and close to: ZBTB5, ZCCHC7, and 
PAX5 on chromosome 9 (Bertrand et al., 2007; Le 
Gouill et al., 2007; Johnson et al., 2009). 
- ZBTB5 is a POZ domain Krüppel-like zinc finger 
transcription repressor. ZBTB5 interacted with co-
repressor-histone deacetylase complexes such as 
BCOR, NCOR1, and NCOR2 (SMRT), resulting in 
deacetylation of histones Ac-H3 and Ac-H4, and 
transcriptional repression of CDKN1A (p21) (Koh 
et al., 2009). 
- ZCCHC7 is the equivalent of the yeast AIR1. In 
yeast, a number of unwanted RNA transcripts are 
first recognized by the nuclear exosome cofactor 
Trf4/5p-Air1/2p-Mtr4p polyadenylation (TRAMP) 
complex before subsequent nuclear-exosome-
mediated degradation.  
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TRAMP facilitates pre-mRNA splicing (Kong et 
al., 2013). 
- PAX5 is a lineage-specific transcription factor; 
recognizes the concensus recognition sequence 
GNCCANTGAAGCGTGAC, where N is any 
nucleotide. Involved in B-cell differentiation.  
Entry of common lymphoid progenitors into the B 
cell lineage depends on E2A, EBF1, and PAX5; 
activates B-cell specific genes and represses genes 
involved in other lineage commitments.  
Activates the surface cell receptor CD19 and 
represses FLT3.  
PAX5 physically interacts with the RAG1/RAG2 
complex, and removes the inhibitory signal of the 
lysine-9-methylated histone H3, and induces V-to-
DJ rearrangements.  
Genes repressed by PAX5 expression in early B 
cells are restored in their function in mature B cells 
and plasma cells, and PAX5 repressed (Fuxa et al., 
2004; Johnson et al., 2004; Zhang et al., 2006; 





DNA binding protein.  
Binds DNA as a heterodimer with MAX.  
Involved in various cellular processes including cell
growth, proliferation, cell adhesion, apoptosis, 
angiogenesis, and stem cell behaviour modulation. 
 
 
Result of the chromosomal 
anomaly 
Fusion protein 
Expression / Localisation 
There was abundant MYC expression in all the 
cases studied. 
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